Hemangioendothelioma

This is a rare type of blood vessel growth (tumor) in the nervous system. It's not usually cancer, but it can sometimes be related to cancer. It's made up of blood vessel cells.

Condition

What people with Hemangioendothelioma report

Every report comes from a Lived member, sent anonymously.

Have you had Surgery for Hemangioendothelioma?

NameHow it went

About Hemangioendothelioma

What It Is

Hemangioendothelioma is a family name for several rare tumors that grow from endothelial cells, the cells that line the inside of blood vessels. They sit between harmless vascular growths, such as common hemangiomas, and angiosarcoma, a fast-growing vascular cancer. Because the name covers tumors that behave very differently, knowing the exact type matters more than the family name itself. Two types account for most of what people need to know. Epithelioid hemangioendothelioma (EHE) is classified as a rare cancer, a type of sarcoma. It is most often found in adults in their thirties to fifties and usually involves the liver, lungs or bones, often in more than one place by the time it is found. It frequently grows slowly, but its course varies widely from person to person. Kaposiform hemangioendothelioma (KHE) mainly affects babies and young children, and about half of cases are present at birth. It does not spread to distant organs, but it grows into surrounding tissue and can trigger a serious bleeding and clotting problem. Other types, including pseudomyogenic, retiform and composite hemangioendothelioma, mostly appear in the skin, soft tissue or bone of young adults. They tend to come back where they started after treatment but rarely spread elsewhere.

Causes & Risk Factors

No lifestyle factor, injury or exposure is known to cause any type of hemangioendothelioma, and nothing a person or parent did is thought to bring one on. The tumors appear to arise from changes in genes that happen within the tumor cells themselves during a person's life, rather than being inherited. In EHE, nearly all tumors carry a specific fusion of two genes that switches on growth signals inside the cell. In KHE, researchers have found changes in growth pathways that control how blood and lymph vessels form. These findings help pathologists confirm the diagnosis and have guided drug choices, but they do not explain why one person develops the tumor and another does not.

How It's Diagnosed

Because these tumors are uncommon and can resemble other conditions, diagnosis usually involves imaging followed by a tissue sample. MRI and CT scans show the tumor's size, how deeply it reaches into nearby tissue and whether other organs are involved. In EHE, scans often show several small spots in the liver or lungs, which can look like cancer that has spread from somewhere else. A biopsy, usually with a needle, lets a pathologist examine the cells under a microscope. For EHE, tests for its characteristic gene fusion help separate it from look-alikes such as angiosarcoma or carcinoma. Experts recommend a second review by a pathologist at a sarcoma center when the first diagnosis was made elsewhere, because the tumor is easy to misclassify. In infants, KHE is often recognized from a firm, purplish, poorly defined swelling, together with imaging and blood tests. A blood count showing a very low platelet level (platelets are the cell fragments that help blood clot) and low fibrinogen, a clotting protein, points to Kasabach-Merritt phenomenon. When that is present, a biopsy can cause dangerous bleeding, so specialists often diagnose and start treatment without one.

Treatment Options

Treatment depends on the type, where the tumor is and whether it has spread, and it is best planned by a team experienced with rare tumors, such as a sarcoma center or a vascular anomalies center. For EHE that is limited to one site, surgery to remove the whole tumor with a margin of healthy tissue is the main treatment and is expected to cure most people, although some tumors still return. Radiation can be added when margins are close or used when surgery is not possible. When EHE is in several places but causes no symptoms, experts generally recommend watching it with regular scans first, because it can stay stable for years and early treatment may do more harm than good. Selected people with EHE confined to the liver may be offered a liver transplant. For disease that is growing or causing symptoms, doctors use medicines off label, since none is approved specifically for EHE. Standard sarcoma chemotherapy works poorly; mTOR inhibitors such as sirolimus, which block a cell growth pathway, have shown the most activity in small studies, often holding the disease in check for about a year. Clinical trials are an important option, and palliative care to manage pain and other symptoms can be part of care at any stage. For KHE, medicine is the mainstay because the tumor is often too infiltrative to remove safely. Sirolimus is now widely used first, often with a short course of steroids, and most children respond, with platelet counts in Kasabach-Merritt phenomenon often starting to improve within days. Because sirolimus weakens the immune system, children taking it need blood level checks, usually avoid live vaccines and may take antibiotics to prevent certain infections. Vincristine, a chemotherapy drug given by vein, is an alternative or addition; it works more slowly and can cause nerve symptoms and constipation. Small tumors without blood problems may be removed or simply observed. The less common types are usually treated with surgery, with follow-up to catch a local recurrence early.

What to Expect

The outlook differs greatly by type. Many people with EHE live for years, sometimes with tumors that stay unchanged for long stretches, while a smaller group has a faster course. Fluid around the lungs or abdomen, weight loss, fever and fatigue are linked with more active disease. After surgery, scans such as MRI and CT are commonly repeated about every six months for the first four to five years, then yearly. Living with a rare cancer that may need monitoring rather than immediate treatment can be emotionally demanding, and patient groups dedicated to EHE can help with information and support. Pain from EHE can flare and may need a specialized approach. For children with KHE, treatment often lasts months to more than a year. Even after a good response, some tumor tissue nearly always remains. It can cause long-term pain, stiff joints or limb swelling (lymphedema) when the tumor involved muscle, bone or a large area of a limb. Residual tissue can also become active again, particularly during the teenage years or after an infection, injury or surgery, which is why yearly checkups with blood tests continue long term. The intermediate types usually have a good outlook after complete removal, with follow-up visits to check the original site.

When to Seek Help

See a doctor about any lump, discolored patch or area of persistent pain that is growing or not going away, and ask for referral to a specialist center if a hemangioendothelioma is suspected or diagnosed. If you have EHE, tell your care team promptly about new breathlessness, a swollen abdomen, unexplained weight loss, fever, fatigue or worsening pain, since these can signal change that may need treatment. For a baby or child with a known or suspected KHE, contact the specialist team the same day if the lump quickly grows, becomes tense, swollen or painful, or if new bruising, tiny red-purple spots or unusual bleeding appear. These can be signs of Kasabach-Merritt phenomenon. Bleeding that will not stop or vomiting blood needs emergency care.

Questions to Ask Your Doctor

  1. 1.Which type of hemangioendothelioma is this, and has the diagnosis been confirmed by a pathologist experienced with rare vascular tumors?
  2. 2.Is treatment needed now, or would watching with regular scans be reasonable, and what would make us change course?
  3. 3.What are the realistic goals and main trade-offs of the treatment you recommend, and are there clinical trials I should consider?
  4. 4.What follow-up schedule will I or my child need, and for how many years?
  5. 5.Which changes in symptoms or blood test results should prompt me to contact you before the next scheduled visit?

Last reviewed • Oct 2026

Educational content, not medical advice.